Evidence map›Paper›PMID 41888815›Full record

ArticleJournal of translational medicine2026

MMP14 is a safe target of CAR-T therapy against liver cancer and metastasis.

Ye Yu, Shirui Zou, Jiawei Fan, Dong Yang, Nan Liu, Zhiyong Bai, Yongjie Zhu, Lihong Li, Dan Cao, Xudong Zhao and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ye Yu *West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
Shirui Zou *Division of Abdominal Tumor Multimodality Treatment and Laboratory of Cell Engineering & Immunotherapy, Cancer Center and State Key Laboratory of Respiratory Health and Multimorbidity and Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
Jiawei Fan *General (Specialized) Department, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, Sichuan, 610041, China.
Dong YangDivision of Abdominal Tumor Multimodality Treatment and Laboratory of Cell Engineering & Immunotherapy, Cancer Center and State Key Laboratory of Respiratory Health and Multimorbidity and Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
Nan LiuDivision of Abdominal Tumor Multimodality Treatment and Laboratory of Cell Engineering & Immunotherapy, Cancer Center and State Key Laboratory of Respiratory Health and Multimorbidity and Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
Zhiyong BaiDivision of Abdominal Tumor Multimodality Treatment and Laboratory of Cell Engineering & Immunotherapy, Cancer Center and State Key Laboratory of Respiratory Health and Multimorbidity and Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
Yongjie ZhuDivision of Abdominal Tumor Multimodality Treatment and Laboratory of Cell Engineering & Immunotherapy, Cancer Center and State Key Laboratory of Respiratory Health and Multimorbidity and Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
Lihong LiKunming Institute of Zoology & National Resource Center for Non-Human Primates, Chinese Academy of Sciences, Kunming, Yunnan, 650223, China.
Dan CaoDivision of Abdominal Tumor Multimodality Treatment, Department of Medical Oncology, Cancer Center and State Key Laboratory of Biological Therapy, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
Xudong ZhaoDivision of Abdominal Tumor Multimodality Treatment and Laboratory of Cell Engineering & Immunotherapy, Cancer Center and State Key Laboratory of Respiratory Health and Multimorbidity and Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
Jiaqiong ZouWest China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan, 610041, China. jiaqiongzouxyj@163.com.

Funding

Sichuan Science and Technology Program 2024ZYD0064West China Hospital, Sichuan University ZYYC20002
6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) is one of the most lethal tumors, and effective treatments for HCC, especially metastatic HCC, are lacking. Chimeric antigen receptor (CAR)-T-cell therapy is considered a promising development in cancer treatment, but to date, CAR-T-cell therapy for solid tumors remains limited. Matrix metalloproteinase 14 (MMP14), the only membrane-bound collagenase, is highly expressed in HCC and other solid tumors and plays critical roles in invasion and metastasis.

methodsHere, we aimed to determine whether CAR-T cells targeting MMP14 could effectively treat HCC. CAR-T cells were designed with peptide G (PG) to specifically recognize MMP14. These cells were evaluated for their cancer-killing efficacy in vitro under MMP14-dependent conditions and tested for antitumor activity in a subcutaneous xenograft liver cancer model. Additionally, a spontaneous liver cancer metastasis model was employed to assess the impact of PG-CAR-T cells on metastasis suppression through circulating tumor cells (CTCs) elimination. The safety profile of PG-CAR-T cells was further investigated in both murine and nonhuman primate models.

resultsPG-CAR-T cells demonstrated efficient MMP14-dependent killing of cancer cells in vitro and exhibited antitumor effects in the subcutaneous xenograft liver cancer model. In the metastasis model, PG-CAR-T cells significantly inhibited metastasis by eliminating CTCs. Furthermore, PG-CAR-T cells showed a favorable safety profile in both mice and nonhuman primates.

conclusionThese data support the PG-CAR-T cells for clinical trial of liver cancer.

Indexed as

Carcinoma, HepatocellularImmunotherapy, AdoptiveLiver NeoplasmsMatrix Metalloproteinase 14Receptors, Chimeric AntigenAnimalsCell Line, TumorFemaleHumansMiceNeoplasm MetastasisNeoplastic Cells, CirculatingPeptidesXenograft Model Antitumor AssaysMatrix Metalloproteinase 14PeptidesReceptors, Chimeric AntigenCAR-T-cell therapyLiver cancerMetastasisMMP14Peptide G

Identifiers

PMID41888815
PMCPMC13023198

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.